The company’s lead candidate, VLX-1005, is in development for the treatment of patients with heparin-induced thrombocytopenia (HIT). VLX-1005 has orphan drug designation in the US and has been awarded Fast Track Designation by the US Food and Drug Administration. Second generation therapeutic products are under development for type I diabetes and other immune-mediated and inflammatory diseases.